AstraZeneca PLCAZN
NYSE • Healthcare
$187.72
P/E
27.98
PEG
5.00
FCF Yield
—
Rev Growth YoY
+12.5% YoY
Gross Margin
82.5%
Health Score
7/10
D/E Ratio
0.61
Confidence
LOW
Business Snapshot
AstraZeneca is a global pharmaceutical company focused on developing and commercialising prescription medicines across oncology, cardiovascular, respiratory, and immunology therapeutic areas. It operates in the highly competitive Drug Manufacturers - General industry, ranking among the largest biopharma players by revenue scale. With TTM revenue of $60.44 billion, the company qualifies as a large-cap enterprise by financial scale. A defining characteristic is its industry-leading gross margin of 82.5%, reflecting strong pricing power and a portfolio of patented drugs that command premium reimbursement.
Financial Health
Gross margin improved to 82.5% from 79.9% in the prior year, while net margin stands at 17.2%, indicating solid profitability and operating leverage. The balance sheet is healthy, with a debt/equity ratio of 0.61x — well below the 1.5x threshold that would signal stress — though the current ratio of 0.94x suggests short-term liquidity is tight, as current liabilities slightly exceed current assets...
Risk Assessment
- VALUATION — P/E of 27.98x is 27% above the sector average of 22x, leaving the stock vulnerable to multiple compression if growth disappoints.
- EARNINGS QUALITY — The company beat analyst estimates in only 1 of the last 4 quarters, which raises questions about guidance reliability and earnings predictability.
- REVENUE DECELERATION — While YoY revenue growth is 12.5%, the sequential quarterly decline of 1.4% flags a potential softening that contrasts with the top-line acceleration narrative.
- DEBT / LIQUIDITY — The current ratio of 0.94x is below the 1.0x threshold, indicating that current liabilities exceed current assets and short-term financial flexibility is constrained.
- TECHNICALS — RSI, MACD, and moving average data unavailable for this period; momentum cannot be independently confirmed....